Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancer.

× No keyword cloud information.

16 in total

1. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

Authors: Charles Huggins; Clarence V Hodges
Journal: J Urol Date: 2002-07 Impact factor: 7.450

2. Abiraterone acetate is well tolerated without concomitant use of corticosteroids.

Authors: Gerhardt Attard; Alison H M Reid; Johann S de Bono
Journal: J Clin Oncol Date: 2010-08-30 Impact factor: 44.544

3. Treatment options in metastatic renal carcinoma: an embarrassment of riches.

Authors: Nicholas J Vogelzang
Journal: J Clin Oncol Date: 2005-12-05 Impact factor: 44.544

Review 4. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis.

Authors: Howard I Scher; Charles L Sawyers
Journal: J Clin Oncol Date: 2005-11-10 Impact factor: 44.544

Review 5. New therapies for castration-resistant prostate cancer: efficacy and safety.

Authors: Himisha Beltran; Tomasz M Beer; Michael A Carducci; Johann de Bono; Martin Gleave; Maha Hussain; William K Kelly; Fred Saad; Cora Sternberg; Scott T Tagawa; Ian F Tannock
Journal: Eur Urol Date: 2011-05-04 Impact factor: 20.096

6. Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17,20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysis.

Authors: M G Rowlands; S E Barrie; F Chan; J Houghton; M Jarman; R McCague; G A Potter
Journal: J Med Chem Date: 1995-10-13 Impact factor: 7.446

7. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.

Authors: Jennifer A Locke; Emma S Guns; Amy A Lubik; Hans H Adomat; Stephen C Hendy; Catherine A Wood; Susan L Ettinger; Martin E Gleave; Colleen C Nelson
Journal: Cancer Res Date: 2008-08-01 Impact factor: 12.701

8. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.

Authors: R Bruce Montgomery; Elahe A Mostaghel; Robert Vessella; David L Hess; Thomas F Kalhorn; Celestia S Higano; Lawrence D True; Peter S Nelson
Journal: Cancer Res Date: 2008-06-01 Impact factor: 12.701

9. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

Authors: Gerhardt Attard; Alison H M Reid; Timothy A Yap; Florence Raynaud; Mitch Dowsett; Sarah Settatree; Mary Barrett; Christopher Parker; Vanessa Martins; Elizabeth Folkerd; Jeremy Clark; Colin S Cooper; Stan B Kaye; David Dearnaley; Gloria Lee; Johann S de Bono
Journal: J Clin Oncol Date: 2008-07-21 Impact factor: 44.544

10. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.

Authors: Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan
Journal: Clin Cancer Res Date: 2008-10-01 Impact factor: 12.531

1 in total

1. The prognostic factors of effective ketoconazole treatment for metastatic castration-resistant prostate cancer: who can benefit from ketoconazole therapy?

Authors: Guo-Wen Lin; Xu-Dong Yao; Ding-Wei Ye; Yao Zhu; Shi-Lin Zhang; Bo Dai; Hai-Liang Zhang; Yi-Jun Shen; Chun-Guang Ma
Journal: Asian J Androl Date: 2012-08-20 Impact factor: 3.285

1 in total